JPRN-UMIN000006195已完成1 期
Phase 1 study of once-daily and alternate-day oral administration of S-1 in patients with locally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancer - Phase 1 study of once-daily and alternate-day oral administration of S-1 in patients with locally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Interstitial pneumonia or pulmonary fibrosis. 2) Watery diarrhea. 3) Severe infections (without viral hepatitis) or being suspected (fever evaluation >=38 degrees). 4) Serious complication (heart failure, renal disorder, liver disorder, bleeding digestive ulcer, intestinal tract paralysis, and etc. ). 5) Moderate or greater pleural effusion, ascites fluid (requiring drainage). 6) Cerebral metastasis. 7) Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration to be within 3 year) except carcinoma in situ or intramucosal cancer. 8) Patients who require administration of flucytosine, phenytoin, and warfarin. 9) Pregnant females or nursing mothers who can not stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period. 10) Serious mental disorder. 11) Drug hypersensitivity. 12) Patients who are judged by doctors inappropriate to perform the study safely.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 12.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaBenign prostatic hyperplasiaEUCTR2009-016800-22-FREli Lilly and Company Limited575
进行中（未招募）
不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) - BPAEMedDRA version: 9.1Level: LLTClassification code 10004446Benign prostatic hyperplasiaEUCTR2009-016800-22-ITEli Lilly and Company Limited575
进行中（未招募）
不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 12.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaBenign prostatic hyperplasiaEUCTR2009-016800-22-GREli Lilly and Company Limited575
进行中（未招募）
不适用
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH). - BPAEMedDRA version: 13.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersBenign prostatic hyperplasiaEUCTR2009-016800-22-DEEli Lilly and Company Limited575
已完成
不适用
A phase I study of the combination of daily oral SU11248 (Sunitinib) with intravenous ifosfamide in patients with advanced solid malignancies.NL-OMON30366Erasmus MC, Universitair Medisch Centrum Rotterdam72